The effect of Neuragen PN on neuropathic pain: A randomized, double blind, placebo controlled clinical trial.
BACKGROUND
A double blind, randomized, placebo controlled study to evaluate the safety and efficacy of the naturally derived topical oil, "Neuragen PN" for the treatment of neuropathic pain.


METHODS
Sixty participants with plantar cutaneous (foot sole) pain due to all cause peripheral neuropathy were recruited from the community. Each subject was randomly assigned to receive one of two treatments (Neuragen PN or placebo) per week in a crossover design. The primary outcome measure was acute spontaneous pain level as reported on a visual analog scale.


RESULTS
There was an overall pain reduction for both treatments from pre to post application. As compared to the placebo, Neuragen PN led to significantly (p < .05) greater pain reduction. Fifty six of sixty subjects (93.3%) receiving Neuragen PN reported pain reduction within 30 minutes. This reduction within 30 minutes occurred in only twenty one of sixty (35.0%) subjects receiving the placebo. In a break out analysis of the diabetic only subgroup, 94% of subjects in the Neuragen PN group achieved pain reduction within 30 minutes vs 11.0% of the placebo group. No adverse events were observed.


CONCLUSIONS
This randomized, placebo controlled, clinical trial with crossover design revealed that the naturally derived oil, Neuragen PN, provided significant relief from neuropathic pain in an all cause neuropathy group. Participants with diabetes within this group experienced similar pain relief.


BACKGROUND
ISRCTN registered: ISRCTN13226601.
Li
Li
L
Department of Kinesiology, Louisiana State University, Baton Rouge, 70803, USA. lli3@lsu.edu
D000287:Administration, Topical; D000368:Aged; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006705:Homeopathy; D006801:Humans; D008297:Male; D008419:Materia Medica / Q000627:therapeutic use*; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology; D009822:Oils, Volatile / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000188:drug therapy*; D010758:Phosphorus / Q000627:therapeutic use; D010936:Plant Extracts / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology
D004338:Drug Combinations; D008419:Materia Medica; D009822:Oils, Volatile; D010936:Plant Extracts; D010758:Phosphorus